{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027751","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-06-08T21:00:43+00:00","discovered_at":"2026-06-08T21:02:00.369681+00:00","generated_at":"2026-06-08T21:02:54.360387+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Mira Pharmaceuticals appoints fractional CFO after CFO Weichselbaum departs","bullets":["Alan Weichselbaum resigned as CFO effective June 6, 2026, with no disagreement with the company.","Andriy Mushak, CPA with over 20 years SEC experience, appointed fractional CFO effective June 6, 2026.","Mushak will serve via consulting agreement with LMAM Consulting Group; company to pay $6,000 per month.","Mushak's expertise includes SEC reporting, audit readiness, internal controls, and capital-markets support."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027751","json":"https://secwatch.observer/filing/0001493152-26-027751.json","markdown":"https://secwatch.observer/filing/0001493152-26-027751.md","text":"https://secwatch.observer/filing/0001493152-26-027751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/0001493152-26-027751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:02:54.360387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a59bfcbe3","claim":"Andriy Mushak was appointed as fractional Chief Financial Officer at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/0001493152-26-027751-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"fractional Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d0106df3f9","claim":"Alan Weichselbaum resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226027751/0001493152-26-027751-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}